

MAP Pharmaceuticals, Inc.

Form 3

October 04, 2007

FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB
Number: 3235-0104Expires: January 31,
2005Estimated average
burden hours per
response... 0.5**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *Skyline Venture Partners
Qualified Purchaser Fund III,
L.P.

(Last) (First) (Middle)

125 UNIVERSITY
AVENUE,, GARDEN LEVEL

(Street)

PALO ALTO, CA 94301

(City) (State) (Zip)

2. Date of Event Requiring
Statement(Month/Day/Year)
10/04/20073. Issuer Name and Ticker or Trading Symbol
MAP Pharmaceuticals, Inc. [MAPP]4. Relationship of Reporting
Person(s) to Issuer

(Check all applicable)

____ Director ____X____ 10% Owner
____ Officer ____ Other
(give title below) (specify below)5. If Amendment, Date Original
Filed(Month/Day/Year)6. Individual or Joint/Group
Filing(Check Applicable Line)
X Form filed by One Reporting
Person
____ Form filed by More than One
Reporting Person**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security
(Instr. 4)2. Amount of Securities
Beneficially Owned
(Instr. 4)3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)4. Nature of Indirect Beneficial
Ownership
(Instr. 5)Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.****Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative
Security
(Instr. 4)2. Date Exercisable and Expiration
Date
(Month/Day/Year)3. Title and Amount of
Securities Underlying
Derivative Security
(Instr. 4)4. Conversion
or Exercise
Price of
Derivative5. Ownership
Form of
Derivative
Security:6. Nature of
Indirect Beneficial
Ownership
(Instr. 5)

Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
10/10/2007 ⁽²⁾	10/10/2007 ⁽³⁾	Common Stock	779,871 ⁽⁴⁾	\$ 0 ⁽⁵⁾	I	See footnote ⁽⁶⁾
10/10/2007 ⁽²⁾	10/10/2007 ⁽³⁾	Common Stock	320,690 ⁽⁴⁾	\$ 0 ⁽⁵⁾	I	See footnote ⁽⁷⁾
10/10/2007 ⁽²⁾	10/10/2007 ⁽³⁾	Common Stock	538,236 ⁽⁴⁾	\$ 0 ⁽⁵⁾	I	See footnote ⁽⁸⁾

$$\hat{A} \quad \hat{A} \times \hat{A} \quad \hat{A} \quad \hat{A}$$

Edgar Filing: MAP Pharmaceuticals, Inc. - Form 3

respect to the shares of Series D Preferred Stock held by SVPIII, SVPQFIII, and John Freund and Yasunori Kaneko as Managing Directors of SVMIII may be deemed to share voting and investment power with respect to the shares of Series D Preferred Stock held by SVPIII and SVPQFIII. The reporting persons/entities disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.